Both the Pfizer vaccine and the Moderna vaccine were developed with new technology

Both the Pfizer vaccine and the Moderna vaccine were developed with new technology that uses messenger RNA. Neither Pfizer nor Moderna has reported any serious safety issues in their trials so far. An independent group of advisers will review vaccine data to the FDA and the CDC. The FDA will decide whether to grant authorization for emergency use; then, the CDC will decide who gets the vaccine. The advisory committees do not have the authority to make decisions, but they follow other groups’ recommendations, Salmon says. The decision does not end at the time of recommendation, Lee says. “We are always in creating new data as it emerges, so it can ch so that,” she says. Back To the pageYou came from: The page you were from. The CDC will craft guidance for the CDC about prioritizing, who receives the vaccine. First, Salmon said.


The public will view trial data and observe discussions as the Vaccines and Related Biological Products Advisory Committee conducts its review in early December. “It will include public deliberation, and that is a good thing,” Salmon said. Salmon added that this type of transparency would be a crucial way to bolster public trust and combat misinformation. This is particularly important because the pandemic has become heavily politicized.


Reference
Will the Covid vaccine be safe? What the scientists want to see.https://www.nbcnews.com/health/health-news/will-covid-vaccine-be-safe-what-scientists-want-see-n1248466
What is mRNA? How Pfizer and Moderna tapped new tech to …. https://www.nbcnews.com/science/science-news/what-mrna-how-pfizer-moderna-tapped-new-tech-make-coronavirus-n1248054
What Is Homework’s Purpose in a Pandemic?. http://www.ascd.org/publications/newsletters/education-update/oct20/vol62/num10/What-Is-Homework’s-Purpose-in-a-Pandemic%C2%A2.aspx

Guidelines prescribe that one or more antiarrhythmic medications

Guidelines prescribe that one or more antiarrhythmic medications be tested before catheter ablation is considered in patients with atrial fibrillation. First-line ablation could be more effective in preserving sinus rhythm, we’ve discovered. Severe adverse effects resulted in 5 patients who underwent ablation and 6 patients who prescribed antiarrhythmic drug treatment. Patients undergoing initial care for symptomatic, paroxysmal atrial fibrillation had a slightly lower risk of recurrence with catheter cryoballoon ablation than with antiarrHythmicDrug, as measured by continuous heart rhythm testing. The median ratio of time of atrial fibrillation was 0 per cent (interquartile scale, 0 to 0.08) with ablation and 0.13 per cent with drug treatment compared to 0.60 per cent with ablated therapy.

Reference

Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. https://www.nejm.org/doi/full/10.1056/NEJMoa2029980

It is possible to forget that COVID-19 is only a relatively young virus

It is possible to forget that COVID-19 is only a relatively young virus. And with that, experts are also struggling to find ways to handle it. Today, a recent report indicates that one possible cure for the virus may be found in your local pharmacy: traditional sleep aid melatonin.

The November study, which was published in the journal PLOS Biology, analyzed patient results from the Cleveland Clinic COVID-19 registry.1 Researcher found that melatonin use was related to an approximately 30% reduced risk of positive testing for SARS-CoV-2, the virus that triggers COVID-19, after age, race, smoking history, and comorbidity-adjusted scientists. The figures for people in some communities were also higher: Afro-Americans had a 52 percent reduced chance of positive results, while those with diabetes were at a 48 percent lower risk.
Reference

Researchers Identify Melatonin as Possible COVID-19 Treatment. https://www.verywellhealth.com/melatonin-possible-covid-19-treatment-5087816

The spread of the Covid-19 among members in a family group

The spread of the Covid-19 among members in a family group after one individual is infected is “common” and occurs quickly after illness onset, relating to new research through the US Centers for Disease Control and Prevention.

The person exposed or suspected of experiencing Covid-19 should always be isolated before getting tested, and before test outcomes get back to protect others in the home, said the analysis, published Friday when looking at the CDC’s Morbidity and Mortality Weekly Report.

“Because prompt isolation of persons with #COVID-19 can lessen household transmission, persons who suspect which they could have COVID-19 should isolate, stay in the home, and employ an independent bedroom and bathroom if feasible,” wrote a CDC-led team of researchers.
All people in family members should also wear masks all of the time per space, the group said.

Referencehttps://www.cnn.com/2020/10/30/health/household-spread-covid-19-wellness/index.html
Household spread of Covid-19 is common and quick, a new CDC study finds. https://www.cnn.com/2020/10/30/health/household-spread-covid-19-wellness/index.html.

Regeneron Pharmaceuticals has paused critically ill COVID-19 patients’ enrollment

Regeneron Pharmaceuticals has paused critically ill COVID-19 patients’ enrollment with its trial studying the antibody cocktail treatment, which was fond of President Trump earlier this month. The choice is because of potential safety concerns.
The drugmaker on Friday said it was suspending the enrollment of hospitalized #COVID-19 patients requiring high-flow oxygen or mechanical ventilation after an unbiased monitoring committee observed “a potential safety signal and an unfavorable risk/benefit profile at the moment.”

The enrollment of individuals in this category should be on hold, pending the collection and evaluation of additional data.

Trials continue to test the antibody cocktail in hospitalized patients necessitating little if any extra oxygen. Other trials involving mild or moderately ill patients also can move ahead.

The drug has revealed encouraging outcomes. Regeneron on Wednesday said early data confirmed the therapy lowered COVID-19 related medical visits by 57 percent.

Regeneron earlier this month asked the foodstuff and Drug Administration for emergency approval and said it could make doses accessible to the American people free of charge. The drugmaker said it might have sufficient doses for 300,000 people when looking at the coming months.

Reference

Regeneron stops enrolling critically ill COVID-19 patients …. https://news.immitate.com/2020/10/30/regeneron-stops-enrolling-critically-ill-covid-19-patients-for-antibody-drug-trial-thehill-the-hill/.